Meeks, who began treatment in September 2023, experiences improved daily functioning despite ongoing challenges. Leqembi is a monoclonal antibody that targets early Alzheimer's, but risks like brain swelling exist. The rollout faces hurdles, including reimbursement and diagnostic requirements.